520 related articles for article (PubMed ID: 31605230)
21. Recent Advances in Liquid Biopsy in Precision Oncology Research.
Sato Y; Matoba R; Kato K
Biol Pharm Bull; 2019; 42(3):337-342. PubMed ID: 30828064
[TBL] [Abstract][Full Text] [Related]
22. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
23. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
El Achi H; Khoury JD; Loghavi S
Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
25. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
26. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono G; Gerratana L; Bulfoni M; Provinciali N; Basile D; Giuliano M; Corvaja C; Arpino G; Del Mastro L; De Placido S; De Laurentiis M; Cristofanilli M; Puglisi F
Cancer Treat Rev; 2019 Feb; 73():73-83. PubMed ID: 30682661
[TBL] [Abstract][Full Text] [Related]
28. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
29. Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
Rodda AE; Parker BJ; Spencer A; Corrie SR
ACS Sens; 2018 Mar; 3(3):540-560. PubMed ID: 29441780
[TBL] [Abstract][Full Text] [Related]
30. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
[TBL] [Abstract][Full Text] [Related]
31. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA - Current state of play and future perspectives.
De Rubis G; Krishnan SR; Bebawy M
Pharmacol Res; 2018 Oct; 136():35-44. PubMed ID: 30142423
[TBL] [Abstract][Full Text] [Related]
34. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
35. The cornerstone of integrating circulating tumor DNA into cancer management.
Li Z; Yi L; Gao P; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):1-11. PubMed ID: 30419316
[TBL] [Abstract][Full Text] [Related]
36. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
37. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
[TBL] [Abstract][Full Text] [Related]
38. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
39. Cell-free tumour DNA testing for early detection of cancer - a potential future tool.
Barbany G; Arthur C; Liedén A; Nordenskjöld M; Rosenquist R; Tesi B; Wallander K; Tham E
J Intern Med; 2019 Aug; 286(2):118-136. PubMed ID: 30861222
[TBL] [Abstract][Full Text] [Related]
40. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
